RBC Bioscience Corporation

NT$20.60As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6848Healthcare
Country Taiwan
PE (Fwd) •••
TSR 5Y CAGR (5.22%)
Div yield 17.16%
ROE 8.09%
Biotechnology
Beta (5Y) 0.44
PE TTM 14.01
TSR TTM 40.64%
Mkt cap NT$294.0M
ROIC 3.52%
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$24
17.49%
(92.79%)
Hold 10|11|1|9|5
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.31
0.31
0.32
0.34
0.65%
6.22%
1.80%
2.05%
RevenueNT$M
17.67
17.31
17.78
17.76
7.80%
(0.09%)
(2.24%)
0.33%
Peers (US$8.881M)
Cap (US$)
PE
6.746M
—
5.675M
18.97x
Capital
TTM
5Y
10Y
Leveragex
0.063
0.046
0.045
EBIT/Intx
1.079
0.900
0.807
Own earn%
217.12
113.60
106.71
Sh yield%
18.29
25.10
28.48
Owners
Insiders/Inst%
14.08
83.55
Short interest%
4.74
SBC / revenue%
2.79
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
5
Op margin range%
0–11
$1 testx
0.0
Incr. ROIC%
14